ALK and non-small cell lung carcinoma: Although this study targeted patients with NSCLC without EGFR or ALK mutations and included the post-immunotherapy era, our findings were consistent with previous studies targeting patients with different biomarker status or studies conducted in the pre-immunotherapy era [9–12].